Investigational cancer drug targets critical proteins

A drug under study to treat various cancers selectively kills cancer cells because of its affinity for a modified version of a critical heat shock protein they contain, researchers have found.

They found in cancer a modified version of heat shock protein 90, or hsp90, which like most heat shock proteins, promotes cell survival.

They then showed that in breast cancer and leukemia, this modification, called acetylation, confers a strong attraction to investigational drug 17-AAG, says Dr. Yonghua Yang, postdoctoral fellow in molecular oncology in the laboratory of Dr. Kapil Bhalla, director of the Medical College of Georgia Cancer Center.

"17-AAG blocks the activity of hsp90, which normally binds with ATP, an energy source for cells," says Dr. Yang, who received a training award to present his research at the American Association for Cancer Research Annual Meeting April 14-18 in Los Angeles.

An unfortunate side effect is that 17-AAG also immediately induces hsp70, which can compensate for the cell-supporting activity of hsp90, says Dr. Yang, noting that like hsp90, hsp70 presents a modified form in cancer.

The net effect is that while the drug ably finds its target, to maximize effectiveness it may need to be modified or used in conjunction with another drug to also block hsp70, Dr. Yang says. MCG researchers are in discussions with Novartis and Kosan Pharmaceuticals about how to make one or the other happen.

17-AAG doesn't seem to care much for normal hsp90 or hsp70 in healthy individuals, he says. Modifications in cancer result from environmental triggers, including stress and eating a lot of oxidated foods, such as foods fried at high temperatures or stored for a long time more good reasons to relax and eat a well- balanced diet, Dr. Yang says.

The MCG researchers are now looking at the relationship between the modified hsp90 and breast cancer metastasis and developing antibodies t

Contact: Toni Baker
Medical College of Georgia

Page: 1 2

Related biology news :

1. Investigational therapy denosumab increased bone mineral density with twice-yearly dosing
2. Protein chatter linked to cancer activation
3. Newly created cancer stem cells could aid breast cancer research
4. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
5. ESF EURYI award winner aims to stop cancer cells reading their own DNA
6. No evidence that widely prescribed statins protect against prostate cancer
7. A study by the MUHC and McGill University opens a new door to understanding cancer
8. New study suggests Concord grape juice may provide protection against breast cancer
9. New test improves detection of liver cancer
10. High-intensity ultrasound may launch attack on cancer, wherever it lurks
11. Unknotting DNA clue to cancer syndrome

Post Your Comments:

(Date:3/5/2020)... ... March 05, 2020 , ... ... technology . The AlphaSTEM Test™ is the first, and still only, available ... Other technologies that attempt to provide information about the number and quality of ...
(Date:3/4/2020)... ... 04, 2020 , ... VGXI, Inc., a uniquely specialized CDMO ... as a finalist in the category of Best Contract Manufacturing Organization for the ... of a DNA vaccine against the novel coronavirus, COVID-19, under a CEPI funded ...
(Date:3/3/2020)... , ... March 03, 2020 , ... Board-certified oral and ... ND. With over 16 years of training and experience, Dr. Noffze can successfully extract ... wisdom teeth as soon as possible is beneficial to the oral and overall health ...
Breaking Biology News(10 mins):
(Date:2/21/2020)... ... February 21, 2020 , ... Join Forrest Brown, Engineering Services Manager – ... Inc. for an informative session on Wednesday, February 26, 2020 at ... to incorporate into facility design to add manufacturing flexibility in the future, especially for ...
(Date:2/19/2020)... ... 2020 , ... Intech , the leader in contract ... unified global brand identity, as it celebrates its 20th anniversary. , Fueled by ... an enthusiasm for designing and manufacturing state-of-the-art medical devices, Intech has grown leaps ...
(Date:2/11/2020)... BOSTON (PRWEB) , ... February ... ... privately-owned company) is pleased to announce the successful results from a long-term ... stenosis using the Inspan interspinous fixation device (INSPAN LLC). Unlike extension block ...
(Date:2/5/2020)... ... February 04, 2020 , ... Shoreline ... down to the strain level, has announced a new distribution partnership in Asia. ... and other products to companies and research organizations in China, Hong Kong, and ...
Breaking Biology Technology:
Cached News: